Clinic Software
Phenomix Sciences
AI driven precision obesity medicine
About
Phenomix Sciences is a precision medicine obesity biotechnology pioneer on a mission to conquer obesity globally through the science of phenotyping, the understanding of how genes combined with environmental and behavioral factors can inform obesity treatment plans. Mayo Clinic physicians, scientists, and researchers, Drs. Acosta and Camilleri, founded the company under the belief that the key to understanding obesity is unprecedented access to its clinical and molecular information throughout all stages and phenotypes of the disease. Phenomix leverages data intelligence to yield better accuracy in predicting individual patient response to specific weight loss interventions and reducing the variability in weight loss results for patients.
Product
- Value proposition
- An AI-enabled platform that integrates genetic, clinical, and biomarker data to map biological pathways driving weight gain and treatment response, enabling a scalable shift toward systematic precision obesity care and matching patients to the right intervention at the right time.
- Target customers
- clinicians, health systems, obesity care programs
Founders
- Andres Acosta
- Michael Camilleri
Categories
Products
Key features
Technologies
Integrations
Target conditions
Care settings
Traction metrics
Competitors
Investors
News
- Phenomix Sciences: Home · 2026-01-11T00:00:00.000Z
- Phenomix Sciences Launches MyPhenome® Test Directly to... · 2026-06-16T00:00:00.000Z
- Precision, not hype: Phenomix CEO on the future of obesity treatment · 2025-07-30T08:29:49.000Z
- Phenomix Sciences Launches Clinical Trial to Predict GLP-1 Response · 2025-04-08T13:29:00.000Z
- New Mayo Clinic Studies Demonstrate MyPhenome Test Predicts Weight Loss Outcomes Across Treatments, Including GLP-1s and Surgical Interventions · 2026-05-05T13:00:00.000Z
- Obesity care gets personalised: tailoring therapies with Phenomix · 2025-03-04T00:00:00.000Z
